Kinase News and Research

RSS

Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation.

21 Mar 2016

PERK inhibition can be a promising therapeutic strategy for neurodegenerative diseases

A major challenge in the field of neurodegeneration is the unclear understanding of neuronal dysfunction. Elucidation of these patho-mechanisms could result in the identification of novel therapeutic targets. In this article, Bell et al. present an exhaustive literature review highlighting the endoplasmic reticulum (ER) kinase PERK as a crucial contributor to systemic and neurodegenerative disorders.

20 Mar 2016

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate.

17 Mar 2016

Vascular events in CML may not be linked to TKI therapy

The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest.

17 Mar 2016

Real-life data show feasibility of imatinib discontinuation in CML

Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment.

17 Mar 2016

New study reveals why certain cancer drugs not always effective in halting tumor growth

New cancer drugs allow doctors to tailor treatment based on the genetic profile of a patient's tumor. However, these drugs don't work at all in some patients, and they lose their effectiveness in others.

17 Mar 2016

Study could lead to potential new therapeutic target with fewer side effects for hypertension

A team of Vermont investigators has been issued a patent for their discovery of a molecule that rescues damaged blood vessels, yet preserves healthy vessels and could serve as a springboard for a new pharmaceutical therapy with fewer side effects for hypertension - a major risk factor for cardiovascular and kidney disease that effects roughly one in three people in the U.S.

15 Mar 2016

Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients.

15 Mar 2016

Combination drug therapy may stop KRAS-mediated lung adenocarcinoma

Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.

15 Mar 2016

Researchers identify potential drug target in skin for itchy feeling

No matter the trigger -- bug bites, a medication side-effect or an itchy wound -- the urge to scratch can be a real pain. Researchers at the Duke University Medical Center have identified a potential drug target in the skin for that itchy feeling.

14 Mar 2016

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.

13 Mar 2016

PKM2 enzyme plays major role in early steps of wound healing

An enzyme involved in glucose metabolism in cells plays a major role in the early steps of wound healing, a finding that could lead to new therapeutic approaches for wound care, according to researchers at Georgia State University.

11 Mar 2016

Breast cancer can be more aggressive in obese people

An international team of researchers, with the participation of the University of Granada, has revealed new data on why breast cancer has a higher incidence and is more aggressive in obese people. The reason is that peritumoral fat (the fat around the tumor) facilitates the expansion and invasion of cancer stem cells (CSCs), which are responsible of the onset and growth of the tumor.

11 Mar 2016

Popular kidney cancer drugs do not reduce incidence of recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania.

10 Mar 2016

Metabolic syndrome treatment benefits MS patients

Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report.

9 Mar 2016

Study provides critical insight into Warburg effect

PGK1, a glycolytic enzyme, has been found to play a role in coordinating cellular processes crucial to cancer metabolism and brain tumor formation, according to results published in today's online issue of Molecular Cell. The findings may lay the groundwork for improved approaches to diagnosis and treatment of glioblastoma and other cancers.

4 Mar 2016

Researchers discover unexpected mechanism linked to aldosterone-induced heart damage

When the heart begins to fail, the body does everything in its power to fix the situation. But sometimes, those compensatory mechanisms ultimately do more harm than good. Such is the case with the adrenal hormone aldosterone, which stimulates the heart to pump harder, causing greater damage to the heart muscle.

3 Mar 2016

New 3-D microscope allows researchers to look at living cancer cells in controlled microenvironment

UT Southwestern Medical Center researchers have designed and built a microscope capable of creating high-resolution, 3-D images of living cancer cells in realistic, controllable microenvironments.

27 Feb 2016

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).

25 Feb 2016

New study identifies cell communication mechanism

The cells of an organism interact not only with each other but with the extracellular matrix that surrounds them. Increasing evidence is unveiling the relevance of this structure--which is secreted by the cells themselves-- for the correct function of the organism and also for the development of various diseases.

24 Feb 2016

Kinase News and Research

Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

PERK inhibition can be a promising therapeutic strategy for neurodegenerative diseases

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Vascular events in CML may not be linked to TKI therapy

Real-life data show feasibility of imatinib discontinuation in CML

New study reveals why certain cancer drugs not always effective in halting tumor growth

Study could lead to potential new therapeutic target with fewer side effects for hypertension

Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Combination drug therapy may stop KRAS-mediated lung adenocarcinoma

Researchers identify potential drug target in skin for itchy feeling

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

PKM2 enzyme plays major role in early steps of wound healing

Breast cancer can be more aggressive in obese people

Popular kidney cancer drugs do not reduce incidence of recurrence

Metabolic syndrome treatment benefits MS patients

Study provides critical insight into Warburg effect

Researchers discover unexpected mechanism linked to aldosterone-induced heart damage

New 3-D microscope allows researchers to look at living cancer cells in controlled microenvironment

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

New study identifies cell communication mechanism

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News